SM
Seamus Mulligan (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Jazz Pharmaceuticals plc (JAZZ). Across 1 priced purchase filing, the average 21-session return was +13.4% from execution and +6.9% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of JAZZ (101,521 sh across 3 lots, as filed), executed May 9 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+13.4%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+6.9%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$10.0M
shares × price, as filed
Last traded
May 12 2025
Filed May 13 2025
Median ADV $210.9M across their filed names
Open performance→Volume by month
Buys $10.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
JAZZRecent filings
JAZZPURCHASE
Jazz Pharmaceuticals plc
View filing →
$10.0M101,521 sh across 3 lots
Exec May 9 2025
Filed May 13 2025 · 5:30 PM ET